Nonetheless, the available studies appear to be persuasive that patients with CTD who tests positive for anti-TRIM21 have a higher probability of concurrent ILD, and a high titer of anti-TRIM21 correlates with worse outcomes and shorter overall survival in CTD-ILD patients. The gene discussed is TRIM21; the disease is interstitial lung disease.